Across TCGA pan-cancer cohorts, LYG2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LYG2 data layer compared with 28 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LYG2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYG2 expression acts as an unfavorable survival marker.
LIHC, BRCA, and ESCA are the cancer types where LYG2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.